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Abstract Mucopolysaccharidosis type IIIB (MPS IIIB,
Sanfilippo syndrome type B) is a lysosomal storage
disorder caused by deficiency of the enzyme N-acetyl-α-
D-glucosaminidase (NAGLU). Information on the natural
course of MPS IIIB is scarce but much needed in view of
emerging therapies. To improve knowledge on the natural
course, data on all 52 MPS IIIB patients ever identified by
enzymatic studies in the Netherlands were gathered.
Clinical data on 44 patients could be retrieved. Only a
small number (n=9; 21%) presented with a classical MPS
III phenotype; all other patients showed a much more
attenuated course of the disease characterized by a
significantly slower regression of intellectual and motor
abilities. The majority of patients lived well into adulthood.
First signs of the disease, usually mild developmental delay,
were observed at a median age of 4 years. Subsequently,
patients showed a slowing and eventually a stagnation of
development. Patients with the attenuated phenotype had a
stable intellectual disability for many years. Molecular
analysis was performed in 24 index patients. The missense
changes p.R643C, p.S612G, p.E634K, and p.L497V were
exclusively found in patients with the attenuated phenotype.
MPS IIIB comprises a remarkably wide spectrum of disease
severity, and an unselected cohort including all Dutch
patients showed a large proportion (79%) with an attenu-
ated phenotype. MPS IIIB must be considered in patients
with a developmental delay, even in the absence of a
progressive decline in intellectual abilities. A key feature,
necessitating metabolic studies, is the coexistence of
behavioral problems.
Introduction
Mucopolysaccharidosis type III (MPS III, Sanfilippo
syndrome) is an autosomal recessive lysosomal storage
disorder caused by a deficiency of one of the enzymes
involved in the degradation of the glycosaminoglycan
heparan sulphate. Four different MPS III subtypes, MPS
III types A, B, C and D, are recognized based on the
enzyme deficiency involved. Birth prevalences of 0.28 to
4.1 per 100,000 have been reported (Valstar et al. 2008).
Clinical signs, symptoms, and course of the disease are
indistinguishable among the MPS III subtypes. The clinical
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symptom-free interval during the first months of life a
slowing of mental development becomes apparent during
the first phase of the disease, which usually starts between 1
and 4 years of age. This is followed by severe behavioral
problems and progressive intellectual decline during the
second phase which generally starts around 3–4 years.
Finally, with the onset of severe dementia, the behavioral
problems slowly disappear, and all motor functions start to
decline, eventually resulting in complete loss of locomo-
tion, dysphagia, and pyramidal tract lesions. Patients
usually die at the end of the second or beginning of the
third decade of life, although longer survival has been
reported in patients with an attenuated phenotype (Berger-
Plantinga et al. 2004; van Schrojenstein-de Valk and van de
Kamp 1987; Verhoeven et al. 2009).
MPS IIIB (Sanfilippo type B; MIM 252920) is caused
by a deficiency of the enzyme N-acetyl-α-D-glucosamini-
dase (NAGLU; E.C. 3.2.1.50), which hydrolyzes the
α,1 →4 linkage between N-acetylglucosamine and the
neighboring uronic acid. The gene for human α-N-
acetylglucosaminidase (NAGLU) was identified in 1996
and is localized on chromosome 17q21.1 (Zhao et al.
1996). The NAGLU cDNA encodes a 720 amino acid
protein that has six potential N-glycosylation sites (Weber
et al. 1996). Thus far, over 100 different mutations in the
NAGLU gene leading to MPS IIIB have been reported
(Beesley et al. 1998, 2004, 2005; Bunge et al. 1999;
Champion et al. 2010; Chinen et al. 2005; Coll et al. 2001;
Emre et al. 2002; Esposito et al. 2000; Lee-Chen et al.
2002; Moog et al. 2007; Schmidtchen et al. 1998; Tessitore
et al. 2000; Weber et al. 1999; Yogalingam and Hopwood
2001;Z h a oe ta l .1996, 1998). Most mutations are
missense, but nonsense mutations, deletions, insertions,
and splice-site mutations have also been reported.
Allele frequencies of the different mutations are very
low, and most mutations are unique to individual families.
This allelic heterogeneity likely causes the wide spectrum
of clinical phenotypes observed in MPS IIIB (Weber et al.
1999), mainly characterized by a remarkable variability in
the rate of progression (Moog et al. 2007; van de Kamp et
al. 1981; van Schrojenstein-de Valk and van de Kamp
1987; Verhoeven et al. 2009). However, unbiased informa-
tion on the natural course of MPS IIIB is limited.
Although no effective disease-modifying therapy is yet
available for MPS IIIB, several studies on therapeutic
interventions aimed at halting the devastating neurocogni-
tive deterioration show promising results (Di et al. 2009;
Piotrowska et al. 2006; Ponder and Haskins 2007).
However, extensive knowledge on the natural course of
the disorder as well as on potential genotype-phenotype
correlations is needed to evaluate clinical efficacy of
therapy.
In this study we report on the largest unbiased cohort of
MPS IIIB patients to date, and we provide details on both
the clinical history as well as on the molecular basis of
disease, revealing large phenotypic variability and an
association of the sequence variants p.R643C, p.S612G, p.
E634K, and p.L497V with a significantly slower progres-
sion of the disease.
Materials and methods
Recruitment of patients
All patients with MPS IIIB ever diagnosed in the Nether-
lands were identified by retrieving the data from the
combined registries of the four diagnostic centers for MPS
III in the Netherlands (Poorthuis et al. 1999). Parents or
legal representatives of patients were asked to participate in
this study via the physicians who had requested the initial
diagnostic studies. For deceased patients, we asked permis-
sion to study the medical records from the physician who
had requested the initial diagnostic studies.
This study was approved by the Medical Ethical
Committee of the AMC, Amsterdam.
Medical history and clinical examination
All living patients included in this study were seen at the
outpatient clinic by one medical doctor (M.J.V.). A
questionnaire on pregnancy and delivery, first clinical signs
and symptoms, mental and motor milestones, behavioral
problems, sleeping problems, and medical history was filled
out by the parents or caregivers.
For deceased patients, medical records were retrieved,
and all available relevant information was recorded.
Cell culture
Skinfibroblastcultureswereobtainedfromthecelldepository
of the Department of Clinical Genetics, Erasmus Medical
Centre in The Netherlands. The fibroblasts were cultured in
Ham F10 medium (Lonza Biotech) supplemented with 10%
fetal calf serum. The fibroblasts were harvested by trypsiniza-
tion and stored as cell pellet at −80°C.
DNA isolation and sequencing
DNA from the deceased patients was extracted from
fibroblasts using the PureGene kit. DNA extracted from
blood was isolated using Magnetic Separation Module 1
from Chemagen (Baesweiler, Germany).
Genomic DNA was used as a template for the PCR. The
primers were designed using standard software (Primer3).
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NAGLU gene were sequenced. PCR products were purified
using ExoSap-it (USB). Sequencing reactions were per-
formed using the Big Dye Terminator kit according to the
suppliers’s instructions (Applied Biosystems). PCR prod-
ucts were purified with Performa V3 96-well short plates
and analyzed using an ABI 3730 XL analyzer (Applied
Biosystems). The data were analyzed using SeqScape
software (Applied Biosystems).
Statistical analysis
Data were analyzed using SPSS version 16.02 for windows.




In the registry of the Dutch diagnostic centers, records from
52 patients with MPS IIIB from 32 families were present
(Table 1). All had been diagnosed between 1969 and 2008
on the basis of enzymatic studies.
Twenty-six of these 52 patients were alive at the time of
this study and 24 patients could be included for full clinical
studies. For two patients (patients 8.1 and 9.1; Table 1),
clinical data were available until the ages of 38 and 10,
respectively, after which they were lost to follow-up.
Twenty patients of the 52 were deceased at the time of
the study. For 18 of them, extensive information on the
course of the disease could be retrieved. In total, clinical
data for 44 patients were available (Fig. 1).
Mutational analysis was performed in 24 of the 32
families.
Twenty-two patients from 12 families were previously
reported in studies on MPS IIIB (Moog et al. 2007; van de
Kamp et al. 1976; van Schrojenstein-de Valk and van de
Kamp 1987; Verhoeven et al. 2009). Family #19 consists of
two closely related sibships (the fathers of these two
sibships are brothers and the mothers are sisters).
Pregnancy and delivery
Pregnancy and delivery were without remarkable compli-
cations. All patients were born at term, and birth weights
were all within normal range.
First signs and symptoms and diagnosis
After a symptom-free interval, patients presented at a
median age of 4 years (range 1–10 years). The main
symptom at presentation, seen in the majority of patients
(95%), was developmental delay, frequently in combina-
tion with behavioral problems. Two patients were diag-
nosed because of hepatomegaly.
The definitive diagnosis of MPS IIIB in the index patients
was made at a median age of 13 years (range 1–66 years)
Behavioral and sleeping problems
With the exception of three patients (aged 2, 20, and
27 years at the time of the study), all patients were reported
to have behavioral problems. Behavioral problems were
first noted at a median age of 5 years (range 1–44), and
usually consisted of extreme restlessness. In addition,
temper tantrums, crying fits, and aggressive and destructive
behavior were reported. Aggressive behavior was experi-
enced as extremely problematic in several older patients,
due to their preserved motor functions and physical
strength.
Difficulties in falling asleep and/or frequent nocturnal
wakening were reported in 63% of patients. Behavioral
problems as well as sleeping problems were frequently
episodic with periods of improved to even normal behavior
and sleeping patterns.
Hearing and vision
Reliable assessment of vision and hearing is generally not
feasible in MPS III patients because of behavioral problems
and intellectual disability. In most patients hearing was
considered to be (near) normal. Reliable audiometric testing
was performed in 10 patients and revealed hearing prob-
lems in only 2. Visual acuity was measured in 17 patients
and was without abnormalities in 9 patients. Retinitis
pigmentosa was detected in 6 patients, all examined after
the age of 40 years.
Epilepsy
Twenty-two of the 43 patients for whom data were
available developed epilepsy during the course of the
disease. Age of development of epilepsy is shown in
Fig. 2. Patient 18.1, not included as an epileptic patient,
was diagnosed with infantile spasms before the age of
2 years but has been seizure free since. Epilepsy could
easily be controlled in the majority of patients.
Miscellaneous signs and symptoms
The majority of patients (68%) suffered from recurrent
ENT infections during the first years of life. Diarrhea,
usually occurring in episodes, was reported in 70% of
patients. Constipation frequently occurred in older patients.
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Family M/F Birth year Age at time of study or
death (years)
Mutation 1 Mutation 2 Family connections
1.1 F 1972 28 p.R643C p.R643C
2.1 M 1975 # p.R297X ##
3.1 F 1979 # No DNA
4.1 F 1988 20 p.A72_G79dup8 p.A72_G79dup8 Sister patient 4.2
4.2 M 1991 17 p.A72_G79dup8 p.A72_G79dup8 Brother patient 4.1
5.1 M 1952 44† No DNA
6.1 F 1932 69† No DNA
7.1 F 1952 58 p.H248R ##
8.1 M 1968 38# p.R643C p.R643C
9.1 M 1988 10# No DNA
10.1 M 1942 67 p.S612G p.R177W Brother patient 10.2
10.2 F 1950 58 p.S612G p.R177W Sister patient 10.1
11.1 M 1963 14† p.R297X p.R297X
12.1 F 1981 27 p.R643C p.R643C
13.1 F 1949 59 p.D63N ## Aunt patient 14.1
14.1 M 1983 25 p.D63N ## Cousin patient 13.1
15.1 F 1989 19 p.R565W p.E634K
15.2 F 1988 20 p.R565W p.E634K
16.1 F 1953 45† p.L497V p.P521L Sib family 16
16.2 M 1959 50 p.L497V p.P521L Sib family 16
16.3 F 1942 53† p.L497V p.P521L Sib family 16
16.4 M 1951 50† p.L497V p.P521L Sib family 16
16.5 M 1943 65 p.L497V p.P521L Sib family 16
16.6 M 1955 54 p.L497V p.P521L Sib family 16
17.1 M 1965 22† p.R674H p.R674H
18.1 M 1984 25 p.A282V p.Y391C
19.1 F 1947 62 p.R643C p.R643C Sib 19.2, cousin 19.3, 19.4, 19.5, 19.6
19.2 F 1953 56 p.R643C p.R643C Sib 19.1, cousin 19.3, 19.4, 19.5, 19.6
19.3 F 1948 28† p.R643C p.R643C Sib 19.4, 19.5, 19.6, cousin 19.1, 19.2
19.4 M 1951 51† p.R643C p.R643C Sib 19.3, 19.5, 19.6, cousin 19.1, 19.2
19.5 F 1954 54 p.R643C p.R643C Sib 19.3, 19.4, 19.6, cousin 19.1, 19.2
19.6 F 1956 52† p.R643C p.R643C Sib 19.3, 19.4, 19.5, cousin 19.1, 19.2
20.1 M 1969 14† p.R297X p.V75fs Brother patient 21.2
20.2 F 1971 13† p.R297X p.V75fs Sister patient 21.1
21.1 F 1975 # No DNA Sister patient 22.1
21.2 F 1982 # No DNA Sister patient 22.1
22.1 F 1972 20† ## ##
23.1 M 1976 # No DNA Brother patient 24.2
23.2 F 1978 # No DNA Sister patient 24.1
24.1 M 1973 35 p.R565Q p.A72_G79dup8 Brother patient 25.2
24.2 M 1971 29† p.R565Q p.A72_G79dup8 Brother patient 25.1
25.1 M 1997 11 p.S612G p.S612G
26.1 F 2004 4 p.I403T p.A72_G79del8
27.1 F 1991 17† No DNA
28.1 M 1961 48 p.R297X p.S612G Brother patient 29.2
28.2 M 1967 43† p.R297X p.S612G Brother patient 29.1
29.1 M 1988 20 No DNA
30.1 M 2005 2 p.R297X p.S612G
31.1 F 1937 47† p.R643C p.R94_D95delinsPH Sister patient 32.2
31.2 M 1942 50† p.R643C p.R94_D95delinsPH Brother patient 32.1
32.1 M 1962 #† p.R297X p.R676P Brother patient 33.2
32.2 F 1966 #† p.R297X p.R676P Sister patient 33.1
# Lost to follow-up,
† deceased,
## mutation not identified
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leakage, were reported in 10 patients. Two patients showed
left ventricular hypertrophy in combination with severe
stenosis of the aortic valve. Two other patients, both above
the age of 50, had atrial fibrillation.
Hepatosplenomegaly was found in the minority of
patients. In eight patients hepatomegaly was reported, while
splenomegaly was only found in three patients. Hernias
were found in 13 patients: 5 patients had suffered from an
umbilical hernia and 10 patients from an inguinal hernia.
Age at death and cause of death
Eighteen of the 52 patients were deceased at the time of the
study. They had died at a median age of 43.5 years (range
13–69). Information on the cause of death was available for
17 patients. The most common cause of death was
pneumonia (n=7). Other causes of death were withdrawal
of artificial feeding because of profound functional dis-
abilities (n=2), accidental strangulation in restraints (n=1),
pancreatitis (n=1), surgical complications (n=1), aspiration
of blood during a severe nasal bleeding (n=1), and heart
failure (n=1). Three patients died suddenly without a
known cause. Two of these patients were unexpectedly
found dead in their bed at age 17 and 46 years and one
patient died suddenly after an oral feeding at the age of
46 years. All three patients were completely bedridden, and
all three had epilepsy that was well controlled by
antiepileptic drugs. No immediate cause of death was
detected in these three patients. Post mortem studies were
performed in only one (aged 46), also failing to reveal the
cause of death.
Molecular analyses
DNA was available for sequencing of the NAGLU gene in
24 of the 32 MPS IIIB families. In 20 families, two
mutations could be identified. In three families, we were
able to detect only one mutation (families #7, 13, and 14).
In patient 22.1 no mutations were identified. Nineteen
different sequence variants were identified, including 4
insertions, 1 deletion, 13 missense mutations, and 1
nonsense mutation (Table 2). Segregation was verified in
patients 12.1, 25.1, 26.1, and 30.1 (Table 1).
Course of the disease
A remarkably large variability in the course of the disease
was detected with an unusually mild course in the majority
of patients (Fig. 3). Clinical phenotype could be assessed in
42 of the 44 patients for whom clinical data were available,
since two patients, 2 and 4 years old at the time of the
study, were excluded since no reliable phenotype could yet
be assessed. These two patients were identified on the basis
of hepatomegaly and developmental delay, respectively.
Severe phenotype
Patients with the classical severe phenotype of MPS III are
generally fully dependent on external care, wheelchair
dependent as early as their teenage years, and usually die
within the first two decades of life. This severe phenotype
was present in the minority (n=9; 21%) of patients in our
cohort (Patients 4.1, 4.2, 9.1, 11.1, 17.1, 20.1, 20.2, 22.1, Fig. 2 Hazard curve of epilepsy in MPS IIIB patients (n=43)
Fig. 1 Flow diagram of MPS
IIIB patients included in the
study
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these severely affected patients is shown in Fig. 3. First
clinical signs in this group of patients, consisting of
developmental delay, mainly in speech development, were
observed at a median age of 3 years. Patients in this group
lost their ability to speak at a median age of 7.5 years
(range 5–10 years) and the ability to walk at the age of
12 years (range 8–18 years).
DNA was available in seven out of nine of these patients
from four families and revealed mutations in six. Four
different pathogenic mutations were identified: two insertions
[c.214_237dup24 (p.A72_G79dup8) and c.217_221dup5
(p.V75fs)], one nonsense mutation (p.R297X), and one
missense mutation (p.R674H).
Attenuated phenotype
The remaining 33 patients of the 42 for whom data on the
clinical phenotype were available showed an attenuated
phenotype, characterized by a much slower regression of
intellectualandmotor abilities(Fig. 3). Almost all (32) of these
patients are adults or lived into adulthood. First clinical signs
in this group were observed at a median age of 4 years, when
a mild developmental delay was observed in all patients,
except for one patient who was diagnosed because of
hepatomegaly. Subsequently, a slowing of intellectual devel-
opment eventually followed by full stagnation of development
was observed. These older patients were reported to be able to
function with a stable intellectual disability for many years.
Loss of ability to speak was reported at a median age of
35 years (range 8–68 years) and of the ability to walk at a
median age of 42.5 years (range 18–68 years). Diagnosis is
this group of patients was made at a median age of 28 years.
Twelve of these 33 patients with an attenuated pheno-
type descended from two large families (families #16 and
19, Table 1). These 12 patients have been previously
reported (Moog et al. 2007; van de Kamp et al. 1976, 1981;
van Schrojenstein-de Valk and van de Kamp 1987).
The six patients from family #19 were homozygous for
the pathogenic mutation p.R643C. This mutation was also
detected in homozygous form in patients 1.1, 8.1, and 12.1
and in combination with an insertion [c.281_283delinsCCC
(p.R94_D95delinsPH), unclassified variant] in the two
patients from family #31. The six patients in family #16
were compound heterozygous for the combination of the
missense changes p.L497V and p.P521L.
The two brothers with MPS IIIB from family #24 also
showed an attenuated phenotype. One of the two brothers
died at the age of 29 due to complications of pancreatitis.
The other patient is currently alive at the age of 35 years.
He is wheelchair bound, but makes social contact and is
able to eat with assistance. These patients were found to be
compound heterozygous for p.R565Q and c.214_237dup24
(p.A72_G79dup8).
Table 2 Sequence variants
Nucleotide change Amino acid change Reference
c.187G>A p.D63N Not previously reported
c.214_237del24 p.A72_G79del8 Not previously reported
c.214_237dup24 p.A72_G79dup8 Bunge et al. 1999 (published as c.238ins24)
c.217_221dup5 p.V75fs Tessitore et al. 2000
c.281_283delinsCCC p.R94_D95delinsPH Not previously reported
c.529C>T p.R177W Verhoeven et al. 2009
c.743A>G p.H248R Weber et al. 1999
c.845C>T p.A282V Not previously reported
c.1172A>G p.Y391C Not previously reported
c.889C>T p.R297X Zhao et al. 1998, Weber et al. 1999
c.1208T>C p.I403T Not previously reported
c.1489C>G p.L497V Not previously reported
c.1562C>T p.P521L Zhao et al. 1998, Beesley et al. 1998, Weber et al. 1999
c.1693C>T p.R565W Beesley et al. 1998, Weber et al. 1999
c.1694G>A p.R565Q Bunge et al. 1999
c.1834A>G p.S612G Zhao et al. 1998
c.1900G>A p.E634K Not previously reported
c.1927C>T p.R643C Weber et al. 1999
c.2021G>A p.R674H Zhao et al. 1998
c.2027 G>C p.R676P Weber et al. 1999
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families with an attenuated phenotype (families #10, 25, and
28). Patients from family #28, who are compound heterozy-
gous for the p.S612G and the pathogenic nonsense mutation
p.R297X, showed an attenuated phenotype. One of these
patients died at the age of 43 years due to pneumonia. His
brother at the current age of 47 years showed a progressive
intellectualdecline fromthe age of30years,but heisstill able
to read and write simple words. His developmental age was
6 years (WISC-III) at the age of 47 years.
An 11-year-old boy was found to be homozygous for the
missense change p.S612G. This patient shows an extremely
mildMPSIIIBphenotypeandisabletoreadandwrite andhis
intellectual functions still improve. Developmental testing
(WISC-III) revealed an IQ of 53, corresponding with a
developmental age of 6.5 years.
The remaining two patients (family #10) have recently
been reported (Verhoeven et al. 2009). These patients also
show an extremely attenuated phenotype. The female
patient (patient 10.2) is, as far as we know, the first woman
with Sanfilippo syndrome to have both married and given
birth to a child. Her brother (patient 10.1) is currently
67 years old. Developmental testing in this 67-year-old man
revealed a developmental age of 2 years and 7 months
(BSID-II). In this family, the unclassified variant p.S612G
was found in heterozygous form, in combination with the
novel missense change p.R177W.
Discussion
We report on the clinical and molecular characteristics of all
patients ever diagnosed in the Netherlands with MPS IIIB
and provide a complete and unbiased overview of the
clinical course.
Patients included in this study follow the same general
pattern of the disease progression as observed in patients
with the Sanfilippo syndrome (Valstar et al. 2008). After an
initial symptom-free interval, patients usually present with a
slowing of developmental and/or behavioral problems,
followed by progressive intellectual decline resulting in
severe dementia and progressive motor disease.
The present study demonstrates a large variability in the
course of the disease in patients with MPS IIIB, with an
unusual mild course in the majority of patients. This was
previously reported in other studies on Dutch patients with
MPS IIIB (Moog et al. 2007; van de Kamp et al. 1976;
Verhoeven et al. 2009). Patients with the classical severe
phenotype of MPS III become completely dependent on
external care and fully wheelchair dependent during their
teenage years and usually die within the first two decades of
life. This severe phenotype was present in only a minority of
patients with MPS IIIB in this otherwise unbiased Dutch
cohort (n=9; 21%). Molecular analyses revealed two inser-
tions [c.214_237dup24 (p.A72_G79dup8) and
c.217_221dup5 (p.V75fs], one nonsense mutation (p.
R297X), and a missense mutation (p.R674H) in this group
of patients. Patients homozygous or compound heterozygous
for a combination of insertions and nonsense mutation can be
expected to have a severe phenotype. Several insertions in the
NAGLU gene have been reported previously in association
with a severe phenotype. These insertions cause a change in
reading frame resulting in altered full change in amino acid
sequence and/or premature chain termination (Yogalingam
and Hopwood 2001).
Fig. 3 Regression and survival in MPS IIIB patients of different
phenotypes. Loss of walking indicates full loss of independent
walking and loss of speech indicates full loss of speech
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MPS IIIB patients (Yogalingam and Hopwood 2001), and
all patients homozygous for this mutation were severely
affected (Weber et al. 1999; Zhao et al. 1998). Finally the
missense mutation p.R674H has also been reported previ-
ously in association with the severe MPS III phenotype
(Zhao et al. 1998).
A remarkably large number of patients in our cohort
showed an attenuated phenotype of the Sanfilippo syn-
drome, with long lasting stable intellectual disability with
regression only following later in life and with prolonged
survival. The pathogenic mutation p.R643C was found in
five families, including four families with homozygous
form and one family in combination with an insertion. The
mutation p.R643C has previously been reported in associ-
ation with an attenuated phenotype (Weber et al. 1999).
The missense changes p.L497V and p.P521L were
detected in compound heterozygous form in family #16.
The six patients from this family all showed an attenuated
phenotype. The missense change p.P521L has been
reported previously to be associated with a severe pheno-
type (Beesley et al. 1998; Weber et al. 1999; Zhao et al.
1998), suggesting that p.L497V probably conveys an
attenuated phenotype. In the two sibs of family #15, the
missense changes p.E634K and p.R565W were identified in
compound heterozygous form. The p.R565W change has
been reported in association with a severe phenotype
(Beesley et al. 1998; Weber et al. 1999), suggesting that
the p.E634K missense change also conveys an attenuated
phenotype. In vitro studies, expressing the p.L497V and p.
E634K missense changes in cell lines are needed to
demonstrate their functional consequences.
The p.S612G mutation, identified in three families
(families #10, 25, and 28), was also found to be associated
with an attenuated phenotype. This was previously sug-
gested by Zhao et al., who reported an attenuated patient
who was compound heterozygous for p.S612G in combi-
nation with an insertion (Zhao et al. 1998). Our study
reveals p.S612G in five patients with an attenuated
phenotype: in homozygous form in one patient, in
compound heterozygous form in combination with the
severe mutation p.R297X in two patients, and in compound
heterozygous form in combination with the novel missense
change p.R177W in the remaining two patients, confirming
the attenuated nature of the p.S612G mutation.
In conclusion we demonstrate that MPS IIIB conveys a
remarkably broad phenotypic spectrum with over 70% of
patients expressing an attenuated course of the disease in an
otherwise unbiased Dutch cohort. This high percentage of
patients with an attenuated form of MPS IIIB is remarkable
and may be caused by a genetic bias. Indeed, 12 of the 33
patients with an attenuated phenotype reported in this study
are from two large families (families #16 and 19). However,
another explanation might be a high degree of awareness of
MPS III in the Netherlands leading to appropriate metabolic
studies even in patients with a more attenuated phenotype.
The studies on MPS III in the Netherlands by van der
Kamp et al. (1976, 1981) were conducted in close
collaboration with a large number of physicians throughout
the country. This may have increased awareness of the
phenotypic spectrum of MPS III in the Netherlands. The
fact that 17 patients with an attenuated MPS IIIB phenotype
from 14 families not related to any of the large MPS IIIB
families were diagnosed within the last two decades
supports this latter hypothesis.
Although the first clinical signs in these attenuated
patients were observed already at a young age (median:
4 years), the diagnosis of MPS III was frequently made
much later in life (median age at diagnosis: 28 years).
These attenuated patients often functioned with a stable
intellectual disability for many years, and in the majority of
patients Sanfilippo syndrome was only considered as a
possible cause of the disability after onset of a decline in
intellectual capacities. Because of the need for appropriate
genetic counselling as well as in view of emerging new
therapies, MPS IIIB should therefore be included in the
differential diagnosis in patients with a stable developmen-
tal delay, especially in combination with behavioral prob-
lems. Molecular analysis revealed 19 different sequence
variants in this cohort, including a large number of
unclassified variants. Functional in vitro assays will be
needed to prove whether or not these novel variants are
pathogenic.
Finally, we report that the missense changes p.R643C, p.
S612G, p.E634K, and p.L497V in MPS IIIB are likely
associated with an attenuated phenotype. Details on the
natural course of the disease in combination with the
genotype correlations may help in predicting the clinical
course of the disease in newly diagnosed patients and may
prove of essential importance in evaluating the effect of
future therapies.
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